Weiye Deng1, Ting Xu1, Yujin Xu2, Yifan Wang3, Xiangyu Liu4, Yu Zhao5, Pei Yang6, Zhongxing Liao7. 1. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 2. Department of Radiation Oncology, Zhejiang Cancer Hospital, Gongshu District, Hanzhou, People's Republic of China. 3. Department of Experimental Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. 4. Department of Biostatistics and Data Science, School of Public Health, The University of Texas Health Science Center, Houston, Texas. 5. Department of Internal Medicine, Unity Hospital/Rochester Regional Health System, Rochester, New York. 6. Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China. 7. Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Electronic address: zliao@mdanderson.org.
Abstract
INTRODUCTION: The positive-to-resected lymph node ratio (LNR) predicts survival in many cancers, but little information is available on its value for patients with N2 NSCLC who receive postoperative radiotherapy (PORT) after resection. We tested the applicability of prognostic scoring models and heat mapping to predict overall survival (OS) and cancer-specific survival (CSS) in patients with resected N2 NSCLC and PORT. METHODS: Our test cohort comprised patients identified from the Surveillance, Epidemiology, and End Results database with N2 NSCLC who received resection and PORT in 2000-2014. Prognostic scoring models were developed to predict OS and CSS using Cox regression; heat maps were constructed with corresponding survival probabilities. Recursive partitioning analysis was applied to the Surveillance, Epidemiology, and End Results data to identify the optimal LNR cutoff point. Models and cutoff points were further tested in 183 similar patients treated at The University of Texas M. D. Anderson Cancer Center in 2000-2015. RESULTS: Multivariate analyses revealed that low LNR independently predicted better OS and CSS in patients with resected N2 NSCLC who received PORT. CONCLUSIONS: LNR can be used to predict survival of patients with resected N2 NSCLC followed by PORT. This approach, which to our knowledge is the first application of heat mapping of positive and negative lymph nodes, was effective in estimating 3-, 5-, and 10-year OS probabilities. Published by Elsevier Inc.
INTRODUCTION: The positive-to-resected lymph node ratio (LNR) predicts survival in many cancers, but little information is available on its value for patients with N2 NSCLC who receive postoperative radiotherapy (PORT) after resection. We tested the applicability of prognostic scoring models and heat mapping to predict overall survival (OS) and cancer-specific survival (CSS) in patients with resected N2 NSCLC and PORT. METHODS: Our test cohort comprised patients identified from the Surveillance, Epidemiology, and End Results database with N2 NSCLC who received resection and PORT in 2000-2014. Prognostic scoring models were developed to predict OS and CSS using Cox regression; heat maps were constructed with corresponding survival probabilities. Recursive partitioning analysis was applied to the Surveillance, Epidemiology, and End Results data to identify the optimal LNR cutoff point. Models and cutoff points were further tested in 183 similar patients treated at The University of Texas M. D. Anderson Cancer Center in 2000-2015. RESULTS: Multivariate analyses revealed that low LNR independently predicted better OS and CSS in patients with resected N2 NSCLC who received PORT. CONCLUSIONS: LNR can be used to predict survival of patients with resected N2 NSCLC followed by PORT. This approach, which to our knowledge is the first application of heat mapping of positive and negative lymph nodes, was effective in estimating 3-, 5-, and 10-year OS probabilities. Published by Elsevier Inc.
Authors: Mian Xi; Zhongxing Liao; Weiye Deng; Cai Xu; Ritsuko Komaki; Mariela Blum; Wayne L Hofstetter; Linus Ho; Steven H Lin Journal: J Thorac Oncol Date: 2017-03-27 Impact factor: 15.609
Authors: Charlotte Billiet; Stéphanie Peeters; Herbert Decaluwé; Johan Vansteenkiste; Jeroen Mebis; Dirk De Ruysscher Journal: Cancer Treat Rev Date: 2016-10-14 Impact factor: 12.111
Authors: Charlotte Billiet; Herbert Decaluwé; Stephanie Peeters; Johan Vansteenkiste; Christophe Dooms; Karin Haustermans; Paul De Leyn; Dirk De Ruysscher Journal: Radiother Oncol Date: 2013-10-04 Impact factor: 6.280
Authors: Guoshu Bi; Tao Lu; Guangyu Yao; Yunyi Bian; Mengnan Zhao; Yiwei Huang; Yi Zhang; Liang Xue; Cheng Zhan; Hong Fan Journal: Cancer Manag Res Date: 2019-11-06 Impact factor: 3.989